세계의 일차 세포 배양 시장 : 예측(2023-2028년)

The primary cell culture market is estimated to grow at a CAGR of 8.59% during the forecast period.

In biomedical research, primary cell culture is an essential technique that involves isolating and cultivating cells directly originating from living tissues or organs. Cells are extracted from tissues by dissection or biopsy, and they are then grown in an appropriate medium to retain their physiological significance and original properties. Through increased heterogeneity in the study of varied cell populations, the method offers a more accurate model for comprehending biological processes, pharmacological reactions, and toxicological consequences.

Growth drivers in the primary cell culture market

The main driver fueling the primary cell culture market's expansion is the rising incidence of chronic diseases such as diabetes mellitus, cancer, infections, autoimmune disorders, cardiovascular diseases, and nephrological diseases. Furthermore, increased research efforts as a result of this rise in illness among patients have encouraged the widespread use of primary cell cultures.

Rising utilization in cell and gene therapy development

The need for personalized treatments is rising, which can be linked to the expanding usage of regenerative medicine. This factor is further fueling the primary cell culture industry. The use of cell and gene therapies to treat ailments including cancer, genetic abnormalities, and autoimmune diseases holds considerable promise. The primary cell culture plays a crucial part in their growth. They entail the manipulation and alteration of cells or genes to restore or increase their function.

Growing prevalence of cancer

The necessity for primary cell culture is expanding as a result of the growing prevalence of cancer. . For instance, according to WHO forecasts, by 2030, the number of cancer-related fatalities will have increased to almost 17 million worldwide. Additionally, according to ACS Journals from February 2021, there were 10.2 million cancer-related fatalities and around 19.3 million new cases of cancer globally in 2020. Thus, as cancer rates rise globally, there will be an increasing need for innovative therapies, which is expected to fuel primary cell culture market share.

Increasing preference for enzymatic degradation is anticipated to drive the market

The primary cell culture market share is rising due to a strong preference for the enzymatic degradation method over alternative primary cell separation techniques because of its advantages including decreased culturing damage, quick processing, and high output of a representative sample. With the use of several types of enzymes, the tissue is disaggregated while producing a high output of primary cells. The main enzyme employed in this method is crude trypsin. Enzymatic disaggregation is, therefore, the most favoured approach in primary cell culture separation and culture procedures since it has less of a negative impact on the cells and produces a higher yield.

Advancement in biomedical research in 3D cultures using primary cells

Primary cells are regarded to be biologically realistic due to their almost perfect match to the original donor tissue. This demonstrates that primary cells utilized in 3D cell structures are more capable than cell lines of producing physiologically appropriate simulations of multicellular environments found in vivo. Primary cells are frequently employed in 3D cultures because they yield findings that are more accurate than those of traditional cell lines.

Increasing use of primary cell culture in animal cells

The primary cell culture growth is further being driven by the expanding use of animal-origin primary cells for vaccine development. Since animal cells have been well examined and characterized, including those from mice, rats, and pigs, they are useful resources for a variety of scientific applications. They are crucial models for researching disease causes, creating new drugs, and conducting toxicity tests.

North America is predicted to hold a significant market share/ Regional analysis of primary cell culture market

North America is anticipated to dominate the global primary cell culture industry due to its high healthcare costs, expanding elderly population, rising chronic illness rates, and increased government financing. Moreover, the Asia Pacific region is predicted to experience strong growth as a result of the decreased costs connected with stem cell transplantation in the area, which has increased demand and included significant R&D. With major developments in regenerative medicine, stem cell research, and tissue engineering applications, there has also been a boom in the development and production of cell and gene treatments in Asia Pacific region.

Market Key Developments

• In April 2023, AnaBios bought Cell Systems to increase the range of human cells available for drug research.
• In February 2023, Thermo Fisher Scientific, Inc. established a partnership with manufacturing firm Celltrio to provide its clients with a fully automated cell culture system.
• In March 2022, High-purity Kupffer cells were added to BioIVT's collection of human primary hepatic cells to aid in the research and development of new medications for liver diseases.

Segmentation:

By Product

• Primary Cells
• Reagents & Supplements
• Media

By Separation

• Explant Method
• Enzymatic Degradation
• Mechanical Separation
• Others

By Cell Type

• Animal Cells
• Human Cells

By Application

• Cell & Gene Therapy Development
• Vaccine Production
• Model System
• Virology
• Prenatal Diagnosis
• Others

By Geography

• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• Japan
• China
• India
• South Korea
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. INTRODUCTION

• 1.1. Market Overview
• 1.2. Market Definition
• 1.3. Scope of the Study
• 1.4. Market Segmentation
• 1.5. Currency
• 1.6. Assumptions
• 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

• 2.1. Research Data
• 2.2. Assumptions

3. EXECUTIVE SUMMARY

• 3.1. Research Highlights

4. MARKET DYNAMICS

• 4.1. Market Drivers
• 4.2. Market Restraints
• 4.3. Porter's Five Force Analysis
  • 4.3.1. Bargaining Power of Suppliers
  • 4.3.2. Bargaining Power of Buyers
  • 4.3.3. Threat of New Entrants
  • 4.3.4. Threat of Substitutes
  • 4.3.5. Competitive Rivalry in the Industry
• 4.4. Industry Value Chain Analysis

5. PRIMARY CELL CULTURE MARKET, BY PRODUCT

• 5.1. Introduction
• 5.2. Primary Cells
• 5.3. Reagents & Supplements
• 5.4. Media

6. PRIMARY CELL CULTURE MARKET, BY SEPARATION

• 6.1. Introduction
• 6.2. Explant Method
• 6.3. Enzymatic Degradation
• 6.4. Mechanical Separation
• 6.5. Others

7. PRIMARY CELL CULTURE MARKET, BY CELL TYPE

• 7.1. Introduction
• 7.2. Animal Cells
• 7.3. Human Cells

8. PRIMARY CELL CULTURE MARKET, BY APPLICATION

• 8.1. Introduction
• 8.2. Cell & Gene Therapy Development
• 8.3. Vaccine Production
• 8.4. Model System
• 8.5. Virology
• 8.6. Prenatal Diagnosis
• 8.7. Others

9. PRIMARY CELL CULTURE MARKET, BY GEOGRAPHY

• 9.1. Introduction
• 9.2. North America
  • 9.2.1. United States
  • 9.2.2. Canada
  • 9.2.3. Mexico
• 9.3. South America
  • 9.3.1. Brazil
  • 9.3.2. Argentina
  • 9.3.3. Others
• 9.4. Europe
  • 9.4.1. United Kingdom
  • 9.4.2. Germany
  • 9.4.3. France
  • 9.4.4. Spain
  • 9.4.5. Others
• 9.5. The Middle East and Africa
  • 9.5.1. Saudi Arabia
  • 9.5.2. UAE
  • 9.5.3. Israel
  • 9.5.4. Others
• 9.6. Asia Pacific
  • 9.6.1. Japan
  • 9.6.2. China
  • 9.6.3. India
  • 9.6.4. South Korea
  • 9.6.5. Indonesia
  • 9.6.6. Thailand
  • 9.6.7. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 10.1. Major Players and Strategy Analysis
• 10.2. Emerging Players and Market Lucrativeness
• 10.3. Mergers, Acquisitions, Agreements, and Collaborations
• 10.4. Vendor Competitiveness Matrix

11. COMPANY PROFILES

• 11.1. Thermo Fisher Scientific, Inc.
• 11.2. Lonza
• 11.3. Merck KGaA
• 11.4. Corning Incorporated
• 11.5. Danaher
• 11.6. PromoCell GmbH
• 11.7. ATCC
• 11.8. FUJIFILM Irvine Scientific, Inc.
• 11.9. Mattek
• 11.10. Axol Bioscience Ltd